Search - tctmd.com

Displaying 281 - 300 of 325

Sort: Relevancy | Date

News Conference News TCT 2013

PROTECT: ZES Lowers Thrombosis Rates Over SES at 4 Years

October 30, 2013

News Conference News TCT 2013

Innovation in Intervention: Perspectives from Industry

October 30, 2013

Presentation TCT 2013

Twelve-Month Clinical Outcomes from the Optimal Duration of Dual Antiplatelet Therapy Following Treatment with Endeavor (Zotarolimus-Eluting Stent) in Real-World Japanese Patients with Coronary Artery

Presenter: Masato Nakamura

October 29, 2013

Presentation TCT 2013

TCT-8. 6-month versus 12-month dual antiplatelet therapy after implantation of 2nd generation drug-eluting stents with Biolimus-eluting Versus Zotarolimus-eluting stent:...

Presenter: Byoung Kwon Lee

October 29, 2013

Presentation TCT 2013

TCT-10. Differences Between US and non-US Cohorts after PCI and Dual Antiplatelet Therapy: Patient Characteristics, Randomization

Presenter: Laura Mauri

October 29, 2013

News Conference News TCT 2013

Data Evolving for Pharmacological Treatment Strategies for Patients with AF and Valvular Heart Disease

October 29, 2013

News Conference News TCT 2013

Cre8, BioFreedom Polymer-Free DES Show Promise

October 28, 2013

News Conference News TCT 2013

COMFORTABLE AMI: Biolimus-Eluting Stent Bests BMS in STEMI

October 28, 2013

Presentation TCT 2013

LAA Closure in Patients Who Need Dual Antiplatelet Therapy: Rationale and Results

Presenter: Zoltan Turi

October 27, 2013

Presentation TCT 2013

Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials.

Presenter: Salvatore Cassese, Robert Byrne, Tomohisa Tada, Lamin King, Adnan Kastrati

January 31, 2013

Presentation TCT 2013

Individual and Regional Variations in Dual Antiplatelet Therapy Dose and Duration in a Large, Randomized International Trial Comparing Two Drug-eluting Stents: Results From...

Presenter: Laura Mauri, Gabriel Steg, Alexis Matteau, Edoardo Camenzind, Eric Boersma, Pascal Vranckx, Patrick Serruys, William O'Neill, Robert Yeh, William Wijns

January 31, 2013

News Conference News TCT 2012

COMPARE II: Biolimus-Eluting Stent Rivals Everolimus-Eluting Stent in All-Comers Trial

November 02, 2012

News Conference News TCT 2012

Aspirin, Cilostazol Combination Best After Angioplasty for Critical Limb Ischemia

November 01, 2012

News Conference News TCT 2012

Second-Generation DES Safer, More Effective Than BMS in STEMI at 1 Year

October 31, 2012

News Conference News TCT 2012

No Excess Bleeding with EES vs. BMS in Octogenarians Despite Prolonged DAPT

October 26, 2012

News Conference News TCT 2012

Two Trials Examine Device-Based PFO Closure

October 25, 2012

News Conference News TCT 2012

TRILOGY ACS Substudy: Angiography Prior to Prasugrel Therapy Reduces CV Events

October 25, 2012

News Conference News TCT 2012

ADAPT-DES: Poor Clopidogrel Response Not Predictive of 1-Year Mortality

October 25, 2012

Presentation TCT 2012

Contrarian Position: Get Your Heads Out of the Sand! Genomics and Platelet Function Testing Will Revolutionize Tailored Antiplatelet Therapy!

Presenter: Matthew Price

October 24, 2012

Presentation TCT 2012

"Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting...

Presenter: Hyeon-Cheol Gwon

October 24, 2012

Advertisement

PROTECT: ZES Lowers Thrombosis Rates Over SES at 4 Years

Innovation in Intervention: Perspectives from Industry

Twelve-Month Clinical Outcomes from the Optimal Duration of Dual Antiplatelet Therapy Following Treatment with Endeavor (Zotarolimus-Eluting Stent) in Real-World Japanese Patients with Coronary Artery

TCT-8. 6-month versus 12-month dual antiplatelet therapy after implantation of 2nd generation drug-eluting stents with Biolimus-eluting Versus Zotarolimus-eluting stent:...

TCT-10. Differences Between US and non-US Cohorts after PCI and Dual Antiplatelet Therapy: Patient Characteristics, Randomization

Data Evolving for Pharmacological Treatment Strategies for Patients with AF and Valvular Heart Disease

Cre8, BioFreedom Polymer-Free DES Show Promise

COMFORTABLE AMI: Biolimus-Eluting Stent Bests BMS in STEMI

LAA Closure in Patients Who Need Dual Antiplatelet Therapy: Rationale and Results

Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials.

Individual and Regional Variations in Dual Antiplatelet Therapy Dose and Duration in a Large, Randomized International Trial Comparing Two Drug-eluting Stents: Results From...

COMPARE II: Biolimus-Eluting Stent Rivals Everolimus-Eluting Stent in All-Comers Trial

Aspirin, Cilostazol Combination Best After Angioplasty for Critical Limb Ischemia

Second-Generation DES Safer, More Effective Than BMS in STEMI at 1 Year

No Excess Bleeding with EES vs. BMS in Octogenarians Despite Prolonged DAPT

Two Trials Examine Device-Based PFO Closure

TRILOGY ACS Substudy: Angiography Prior to Prasugrel Therapy Reduces CV Events

ADAPT-DES: Poor Clopidogrel Response Not Predictive of 1-Year Mortality

Contrarian Position: Get Your Heads Out of the Sand! Genomics and Platelet Function Testing Will Revolutionize Tailored Antiplatelet Therapy!

"Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting...

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content